Výsledky vyhledávání

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot

Publikováno v: Journal of Thrombosis and Haemostasis. 2:234-241

Summary. Background: Direct factor (F)Xa inhibition is an attractive method to limit thrombotic complications during percutaneous coronary intervention (PCI). Objectives: To investigate drug levels achieved, effect on coagulation markers, and prelimi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d82b580a25bd8434c59c7f0d14b6eb
https://doi.org/10.1111/j.1538-7933.2004.00594.x

Zobrazit plný text záznamu

Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases

Autor: T. Hara, S. Kunitada, Masahiro Iwamoto, Takayasu Nagahara, Shinichi Katakura

Publikováno v: European Journal of Medicinal Chemistry. 30:387-394

Summary Molecular modeling of a complex between factor Xa (FXa) and DX-9065a, a novel FXa inhibitor, has demonstrated a salt-bridge interaction of the amidinonaphthalene moiety of the inhibitor to the S1 site pocket of the enzyme and a crucial carbox

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33ad0362a7376e9a4d576e4c5ec55d2d
https://doi.org/10.1016/0223-5234(96)88248-1

Zobrazit plný text záznamu

[FXa inhibitor]

Autor: S, Kunitada

Publikováno v: Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme. 45

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ca9566c5936563fc82551ebd0694d8ba
https://pubmed.ncbi.nlm.nih.gov/10771691

Zobrazit plný text záznamu

Inhibitors of Factor Xa

Autor: T. Hara, S. Kunitada, T. Nagahara

Publikováno v: Antithrombotics ISBN: 9783642641909

Thrombin occupies a central position in thrombus formation and recently has been a target for the development of anticoagulant agents. As is well known, blood coagulation operates as a cascade or multiple enzymatic amplification process. In the class

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f4c02c703a131e6530d10ad1ed6785e
https://doi.org/10.1007/978-3-642-59942-2_14

Zobrazit plný text záznamu

Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants

Autor: Y, Morishima, K, Tanabe, Y, Terada, T, Hara, S, Kunitada

Publikováno v: Thrombosis and haemostasis. 78(5)

(+)-2S-2-[4-[[(3S)-1-Acetimidoyl-3- pyrrolidinyl]oxy]phenyl]-3-[7-amidino-2-naphthyl]propanoic acid hydrochloride pentahydrate (DX-9065a) is an antithrombin III (AT III)-independent and selective inhibitor of activated blood coagulation factor X (FXa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a2b2d2cf98880c84ad3287893133c82d
https://pubmed.ncbi.nlm.nih.gov/9408021

Zobrazit plný text záznamu

Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction

Autor: S Kunitada, GA FitzGerald, DJ Fitzgerald

Publikováno v: Blood. 79(6)

Tissue-type plasminogen activator (t-PA) is less active in vivo and in vitro against clots that are enriched in platelets, even at therapeutic concentrations. The release of radioactivity from 125I-fibrin-labeled clots was decreased by 47% 6 hours af

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae83219ed425de3fa19630987d0dd234
https://pubmed.ncbi.nlm.nih.gov/1547340

Zobrazit plný text záznamu

Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue

Autor: S Kunitada, David M. Kerins, Garret A. FitzGerald, L Roy, A Adedoyin, Desmond J. Fitzgerald

Publikováno v: Circulation. 85(2)

BACKGROUND Coronary reocclusion complicates the thrombolytic therapy of acute myocardial infarction despite the routine use of aspirin. This is consistent with experimental studies demonstrating that multiple agonists, in addition to thromboxane A2,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e91cf9a0ecdce8091b903771027926d4
https://pubmed.ncbi.nlm.nih.gov/1370924

Zobrazit plný text záznamu

A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction

Autor: D M, Kerins, M, Shuh, S, Kunitada, G A, Fitzgerald, D J, Fitzgerald

Publikováno v: The Journal of pharmacology and experimental therapeutics. 257(1)

Inhibition of thromboxane (TX) A2 with aspirin enhances the response to coronary thrombolysis. However, experimental evidence suggests that platelet activation during coronary thrombolysis is mediated by a number of agonists, in addition to TXA2. As

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2afae62e9971b9ff101364a48c123f96
https://pubmed.ncbi.nlm.nih.gov/1708425

Zobrazit plný text záznamu

Population PK analysis of DX-9065A in patients with acute coronary syndrome

Autor: S. Kunitada, R. Wada, M. Yamaguchi

Publikováno v: Clinical Pharmacology & Therapeutics. 77:P89-P89

Background/Aim To evaluate the population Pharmacokinetics(PK) of DX-9065a(DX). Methods Plasma concentration data from Phase I and patients with Acute Coronary Syndrome (ACS) were modeled using population PK approach (NONMEM®). Design Data from 7 st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0fc59a728777ed4b7ce6c65826bb5e0c
https://doi.org/10.1016/j.clpt.2004.12.232

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání